Aurinia reports Q3 2026 revenue of $83.7M, raising 2026 guidance to $325M-$330M
Aurinia Pharmaceuticals boosted its 2026 revenue guidance as Q3 net product sales of LUPKYNIS rose 12% and total revenue climbed 14%. The company reported Q3 cash balances of $486.9 million.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed